Brief: Ryvu Therapeutics Says Poland's Medicines Authority Allows For Phase I Trial Of SEL120
07/01/2021 16:21
Jan 7 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* POLAND'S MEDICINES AUTHORITY URPL GRANTS PERMISSION TO
COMPANY
FOR PHASE I TRIAL INVESTIGATING SEL120
Source text for Eikon: ID:nEMDnzbJa
Further company coverage: RVU.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Q1 Net Loss 12.6 Million Zlotys
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project